全球疫苗乱象:到底谁才“配得上”新冠疫苗?

当第一批新冠疫苗终于开始分发时,世界为之欢呼雀跃。然而,不到两个月后,新冠疫苗的生产、 运输和分发已然乱象丛生。

1.各国疫苗争夺之战一触即发

真相放大镜 | 全球疫苗乱象:到底谁才“配得上”新冠疫苗?

许多疫苗制造商曾一再向各国政府保证他们的生产力。然而,现实是他们的生产力相当有限,导致各国不得不各自争夺属于本国的疫苗份额。

最近,欧盟正在为此焦头烂额。

辉瑞公司和阿斯利康公司近日突然告知一些欧盟成员国,由于产量的减少,他们不得不削减之前承诺分发给各国的疫苗数量。

Recently, Pfizer has told some EU member states that the amount of vaccines it promised to offer this week has to be halved.

To make matters worse, AstraZeneca, which developed the coronavirus vaccine with Oxford University, told the EU that “it intends to supply considerably fewer doses in the coming weeks than agreed and announced,” according to a press statement by the EU Health Commissioner Stella Kyriakides.